TY - JOUR AU - Behcet, Mustafa AU - Kaya, Ayse Demet PY - 2020/06/13 Y2 - 2024/03/29 TI - Investigation of therapeutic effect of Saccharomyces boulardii and translocation in immunsupressed rats infected with Shigella sonnei JF - EXPERIMENTAL BIOMEDICAL RESEARCH JA - Exp Biomed Res VL - 3 IS - 3 SE - Articles DO - 10.30714/j-ebr.2020361049 UR - https://experimentalbiomedicalresearch.com/ojs/index.php/ebr/article/view/98 SP - 141-148 AB - <p><strong>Aim:</strong> To investigate the therapeutic effects of <em>Saccharomyces boulardii </em>(<em>S. boulardii</em>) and detect blood and tissue penetrations of <em>S. boulardii</em> and <em>Shigella sonnei</em> (<em>S. sonnei</em>) in immunocompromised rats infected with <em>S. sonnei</em>.</p><p><strong>Methods: </strong>Forty rats were divided into four groups: Group A (immunosuppressed, not-treated); Group B (immunosuppressed, treated-with-<em> S. boulardii</em>); Group C (immunosuppressed, infected-with-<em>S.sonnei</em>, treated-with-<em> S. boulardii</em>); Group D (immunosuppressed, infected-with-<em>S. sonnei</em>). After taking samples for blood cultures, the rats were sacrificed. Large bowel, liver, spleen and mesenteric lymph nodes (MLN) were removed for microbiological examination.</p><p><strong>Results:</strong> <em>S. boulardii</em> in group B and <em>S. sonnei</em> in group D were isolated from blood in some rats. Statistical analysis of our data, showed that the numbers of translocated colonies in the liver and spleen were relatively higher for <em>S. boulardii</em> in Group B and for <em>S. sonnei</em> in Group D, without reaching levels of statistical significance. For MLN, colony counts in Group B was higher than Group C and A showing statistical significance.</p><p><strong>Conclusion:</strong> The administration of <em>S. boulardii</em> showed promising results for the therapy of <em>S. sonnei</em> infection in immunosuppressed rats, but therapeutic usage of <em>S. boulardii</em> should be carefully assessed by taking into consideration the risk it poses versus potential benefits in risk groups.</p> ER -